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Background: Epstein-Barr virus (EBV) is an oncogenic virus implicated in the pathogenesis of a number of human
malignancies of both lymphoid and epithelial origin. Thus, a comprehensive and up-to-date analysis focused on the
global burden of EBV-attributable malignancies is of significant interest.
Methods: Based on published studies, we estimated the proportion of Burkitt’s lymphoma (BL), Hodgkin’s
lymphoma (HL), nasopharyngeal carcinoma NPC), gastric carcinoma (GC) and post-transplant lymphoproliferative
disease (PTLD) attributable to EBV, taking into consideration age, sex and geographical variations. This proportion
was then imputed into the Global Burden of Disease 2010 dataset to determine the global burden of each
EBV-attributable malignancy in males and females in 20 different age groups and 21 world regions from 1990 to 2010.
Results: The analysis showed that the combined global burden of deaths in 2010 from all EBV-attributable malignancies
was 142,979, representing 1.8% of all cancer deaths. This burden has increased by 14.6% over a period of 20 years. All 5
EBV-attributable malignancies were more common in males in all geographical regions (ratio of 2.6:1). Gastric cancer
and NPC accounted for 92% of all EBV-attributable cancer deaths. Almost 50% of EBV-attributed malignancies occurred
in East Asia. This region also had the highest age-standardized death rates for both NPC and GC.
Conclusions: Approximately 143,000 deaths in 2010 were attributed to EBV-associated malignancies. This figure
is likely to be an underestimate since some of the less prevalent EBV-associated malignancies have not been
included. Moreover, the global increase in population and life-expectancy will further increase the overall burden
of EBV-associated cancer deaths. Development of a suitable vaccine could have a substantial impact on reducing
this burden.
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Cancer is one of the leading causes of death worldwide
and research focused on understanding the etiology and
pathogenesis of cancer is a major challenge. It has
previously been estimated that oncogenic viruses
play an etiological role in the development of ap-
proximately 12% of all human malignancies [1,2].
The vast majority of these malignancies are caused
by just five different viruses of which Epstein-Barr
virus (EBV) is arguably one of the most extensively
studied [3].* Correspondence: g_khan@uaeu.ac.ae
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article, unless otherwise stated.EBV is a large dsDNA lymphotropic herpesvirus his-
torically associated with Burkitt’s lymphoma, from which
the virus was first isolated 50 years ago [4]. However, ever
since its isolation, EBV has continued to attract consider-
able attention, primarily due to its oncogenic properties
and its association with a number of human malignancies,
including Burkitt’s lymphoma (BL), nasopharyngeal carcin-
oma (NPC), post-transplant lymphoproliferative disease
(PTLD), Hodgkin’s lymphoma (HL) and gastric carcinoma
(GC) [3]. EBV is primarily transmitted via saliva and in
healthy immunocompetent individuals it infects and es-
tablishes life-long latency in memory B-lymphocytes [5,6].
In these cells, the virus limits its gene expression to 1 or 2
viral proteins only, thus escaping the immune surveillance
[7]. This is referred to as type 0/1 latency. In some EBV-
associated malignancies, such as NPC and HL, at least 3
viral genes have been shown to be expressed, includingntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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ferred to as type 2 latency. How the viral infected cells in
these malignancies escape the immune system is unclear.
In contrast, in vitro infection of B-lymphocytes results in
their immortalization and establishment of lymphoblas-
toid cell lines (LCLs) [8]. In these cells, at least a dozen
different EBV latent products are expressed, including 6
Epstein-Barr nuclear antigens (EBNAs), 3 latent mem-
brane proteins (LMPs) and 2 non-protein coding small
RNAs (EBERs) [3]. In addition to these, a number of
micro-RNAs have also been shown to be expressed [9].
This is referred to as type 3 latency or growth program
[10,11]. A substantial body of evidence indicates that a
number of these latent viral products are central for EBV-
induced immortalization of the infected cells. In EBV-
associated malignancies, all three patterns of latency have
been detected, suggesting that EBV induces oncogenesis
by different mechanisms in different malignancies. Al-
though EBV is carried asymptomatically by over 90% of
adults worldwide, induction of cancer by this virus is
nevertheless a very rare event. This clearly indicates that
EBV on its own is not sufficient and other co-factors are
necessary [12-14]. Thus, in order to link EBV in the eti-
ology of a malignancy it is essential to demonstrate the
presence of viral genome and/or gene expression directly
in the tumor cells. This approach has revealed that the
virus is not necessarily etiologically involved in all cases of
a malignancy with which EBV has been implicated
[15,16]. For example, only about 40% of Hodgkin’s
lymphoma cases have EBV in the malignant cells and the
prevalence varies with age [17].
In this study we provide the most up-to-date and de-
tailed descriptive epidemiology of EBV-attributable ma-
lignancies using the Global Burden of Disease, Injuries
and Risk Factors Study 2010 (GBD 2010) dataset. GBD
2010 is the largest and most comprehensive study ever
conducted to measure the global health metrics [18,19].
As far as we are aware, the present study is the first to
use GBD 2010 data to estimate the burden of EBV-
associated malignancies in different age and sex groups
in 21 world geographical regions from 1990 to 2010. It
is hoped that the findings of this study will high-light
the need for potential preventative measures and the
global regions where implementation of such measures
would have the greatest impact.
Methods
EBV associated malignancies
EBV is an accepted carcinogen [20] and experimental
studies have clearly demonstrated that it is present in
the tumor cells of several malignancies, including NPC,
BL, HL, GC and PTLD [3,21]. There is substantial evi-
dence that EBV has a causative role in the pathogenesis
of these malignancies. However, the association is notuniversal and not all cases from all regions are linked to
EBV. Our first step in this study was to estimate the
proportion of these malignancies that can be reliably
attributed to EBV based on published studies.
Estimation of the proportion of EBV-attributable cases
Since EBV is ubiquitous in the general population, EBV-
attributable cancers are defined as those in which viral
DNA/RNA and/or viral gene expression can be demon-
strated in the tumor tissues. Based on published studies,
we estimated the proportion of NPC [1,2], GC [22,23],
HL [17,24-29], BL [1,2] and PTLD [30,31] that are at-
tributable to EBV, taking into consideration any estab-
lished variations that have been reported in different
age, sex and ethnic groups (Table 1). For GC, the pro-
portion of EBV-attributable cases has been reported to
be similar in different world regions [22,32], but varies
significantly with gender [22,33,34]. Based on two large
meta-analysis studies, we have used EBV-attributable es-
timates of 11% and 6% for males and females respect-
ively [22,23]. For HL, there is a general consensus that
the EBV-attributable fraction varies significantly between
different age groups. From the published studies, we
estimated 62%, 30% and 55% of the cases to be attrib-
uted to EBV for the age groups 0-14 years [17,24,27,29],
15-54 years [17,25,27-29], and 55-80+ years [17,26-29]
respectively. For PTLD, we estimated that 80% of PTLD
cases to be attributed to EBV [30,31] (Table 1).
Estimation of the mortality from NPC, GC, HL, BL and
PTLD
Data files for mortality estimates of all cancer cases were
obtained from the Institute of Health Metrics Evaluation
(IHME), University of Washington [35]. Detailed descrip-
tions of how mortality figures were estimated has been
previously published as part of the GBD 2010 study
[36,37]. Briefly, mortality estimates were based on sev-
eral different sources, including surveys, censuses, sam-
ple registration data and vital registration data, and final
estimates derived using a range of statistical models
[36-38]. All mortality figures and rates were estimated
with 95% confidence intervals.
Age and sex-specific mortality estimates in 21 geo-
graphical regions were directly available for NPC, GC
and HL from the GBD 2010 dataset. For BL, mortality
data was not directly available as this malignancy was
part of a broader category of non-Hodgkin’s lymphomas
(NHL). Based on a previous study on the global burden
of infection-associated cancers [1], the proportion of BL
within the larger NHL category in the age group 0-14 years
was estimated to be 90.5%, 33.3% and 15.2% for regions
where BL is endemic, intermediate or sporadic respect-
ively (Table 1). For age group 15-80+, irrespective of geo-
graphical region, the proportion of BL in HIV-negative




EBV in cases (%)
Comment
Nasopharyngeal carcinoma (ICD10:C11) Type II Estimates based on 2 previous studies on global burden of
infection-associated cancer [1,2].
• High/intermediate incidence region 100%
• Low incidence region 80% High/intermediate regions: East Asia, South Asia, South East
Asia & North Africa & Middle East [53]. All other regions
were regarded as low incidence.
Gastric carcinoma (ICD10:C16) Type II Estimate based on 2 large meta-analysis studies with a
cumulative total of 25,690 cases [22,23].
• Males 11%
• Females 6%
Hodgkin’s disease (ICD10:C81) Type II Estimates based on 7 studies with cumulative total of 3357
cases [17,24-29].
• Children <14yrs 62%
• Adults 15-54yrs 30% Age group 0-14 yrs based on 4 studies [17,24,27,29].
• Adults >55yrs 55% Age group 15-54 yrs based on 5 studies [17,25,27-29].
Age group 55+ yrs based on 5 studies [17,26-29].
Burkitt’s Lymphoma (ICD10:C83.5) Type I Estimates based on 2 previous studies on global burden
of infection-associated cancer [1,2].Endemic region:
Sub-Saharan Africa.• Endemic
90.5% of all NHL are BL in 0-14 age group [1]. 95%
• Intermediate Intermediate regions: N. Africa & Middle east, Latin America.
33.3% of all NHL are BL in 0-14 age group [1]. 50%
• Non-endemic Non-endemic: All other regions.
15.2% of all NHL are BL in 0-14 age group [1]. 20% BL is 3-4x more common in males [41-43,45]. In this study
we have used male:female ratio of 3:1.
In adults (age group 15-80+), irrespective of region,
BL is estimated to constitute 2% of all NHL [39].
Post-transplant lymphoproliferative disease
(ICD10:D47.Z1)
Type III 80% of all PTLD were estimated to be due to EBV [30,31]. It
was assumed the risk of developing PTLD and dying from it
was the same for both sexes.
• 1.5% of transplant recipients were estimated to
developed PTLD and 50% of these died with first
year of post-transplant [30,48,49].
80%
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[39]. BL is approximately 3-4 times more common in
males as compared to females [40-45]. In this study we
used male:female ratio of 3:1 in calculating the prevalence
of BL. Thus, all proportions were stratified by age, sex and
region. For estimating the prevalence of PTLD, we used
data from Global Observatory on Donation and Trans-
plantation (GODT), produced by the WHO-ONT collab-
oration [46]. In 2010, a total of 101,990 transplants
(kidney, heart, liver, lung and pancreas) were performed,
approximately 60% of which were on males [47]. Based on
previous reports [30,48], we estimated that approximately
1.5% of transplant recipients develop PTLD and 50% of
these die within the first year of lymphoma development
[30,48,49]. It was assumed that the risk of developing
PTLD and dying from it was the same for both sexes.
Estimation of the mortality from EBV-attributed NPC,
GC, HL, BL and PTLD
The estimates of the proportion of EBV-attributable
death for each malignancy established from the publishedliterature (Table 1) were imputed into GBD 2010 data,
adjusted for age, sex and geographical region. For
example, for BL in East Sub-Saharan Africa, GBD 2010
dataset shows 227 deaths from NHL in males aged 1-4
years. In this region, 90.5% of NHL have been estimated
to be BL cases in this age group [1], with a male predom-
inance of 3:1 [41-45]. Based on this, 227 × 0.905 × 0.75
gives an estimated number of BL cases to be 154. Since
95% of BL cases in this age group and region are associ-
ated with EBV [1,2], the number of EBV-attributed BL
deaths can be estimated to be 146 cases. Using this
approach, we calculated the burden of death from each
EBV-associated malignancy in males and females in 20
different age groups and 21 different geographical regions
for the year 2010. This was then extended for 5 different
time points from 1990 to 2010.
Results
Overall global burden of EBV-attributed malignancies
Over a period of 20 years, global mortality from cancer
has increased from 5.779 million in 1990 to 7.978
Table 2 Global burden of deaths from EBV-attributed malignancies in 2010
Type of
malignancy
Global deaths: All cases Global deaths: EBV-attributed cases % deaths from
EBV-attributed cases (both)Males Females Both Males Females Both
NPC 45,640 19,264 64,904 44,418 18,700 63,118 97.2
BL 3,575 821 4,396 1,820 431 2,251 51.2
HL 10,208 7,510 17,718 4,507 3,410 7,917 44.7
Stomach 475,759 279,132 754,891 52,333 16,748 69,081 9.2
PTLD 459 306 765 367 245 612 80.0
Total 535,641 307,033 842,674 103,445 39,534 142,979 17.0
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per year. However, the collective global number of
deaths from NPC, BL, HL, GC and PTLD has remained
fairly constant (a modest increase of only 0.2%). Of the
total of 842,674 deaths from these 5 malignancies in
2010, 142,979 (17.0%) were calculated to be from EBV-
attributed cases (Table 2). This represents 1.8% of all
cancer deaths in 2010 worldwide. The largest number of
deaths from EBV-attributed malignancies was for gastric
carcinoma (69,081 cases), closely followed by NPC
(63,118 cases). The proportion of cases of NPC, BL, HL,
GC and PTLD, specifically adjusted for age, sex andFigure 1 Global burden of deaths from all EBV-attributed malignancigeographical region, attributable to EBV was 97.2%,
51.2%, 44.7%, 9.2% and 80% respectively (Table 2).
Patterns of EBV-attributed malignancies by geographical
region and time
Analysis of EBV-attributed malignancies in 21 world
regions revealed that the highest mortality was in East
Asia (Figure 1). In fact 47% of all EBV-attributed malig-
nancies occurred in this region. This in turn is a reflec-
tion of the fact that this region, which includes China,
Democratic People’s Republic of Korea and Taiwan, has
by far the highest prevalence of both gastric andes in 2010 by world regions.
Khan and Hashim Infectious Agents and Cancer 2014, 9:38 Page 5 of 10
http://www.infectagentscancer.com/content/9/1/38nasopharyngeal carcinoma in the world (Additional file 1:
Figure S1). Age-standardized mortality rates for these
malignancies in East Asia are also the highest in the world
(Figure 2a and b). Furthermore, unlike the other malig-
nancies, the burden of mortality due to NPC has increased
from 43,828 in 1990, to 63,118 in 2010, an average annual
increase of 2.2% (Figure 3). Although the age-adjusted
death rate of NPC in East Asia is by far the highest in the
world (2.5/100,000 in 2010), the rates have not increased
over the 20 years (Figure 2a). This indicates that theFigure 2 Global burden of age standardized death rates of (a) nasophincrease in burden of NPC observed over the 20 years is
most likely due to an increase in the population at risk.
Patterns of EBV-attributed malignancies by sex and age
Global deaths from EBV-attributed cases of all 5 malig-
nancies were up to 2.6 times higher in males as compared
to females (Figure 4). This difference is likely to be an
underestimate, since we did not take into account the
accumulating data which indicates that males are more
likely than females to have EBV-attributable HL [29,50-52].aryngeal carcinoma and (b) gastric cancer, 1990-2010.
Figure 3 Global burden of deaths from EBV-attributed malignancies, 1990-2010.
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virtually all world regions (Additional file 1: Figure S1).
The reason for this male preponderance is not known, but
male genetics and male lifestyle are plausible risk factors.
Analysis of deaths from these malignancies by age re-
vealed that the vast majority of the cases occurred in
adults, primarily after the age of 35 years (Figure 5). An
exception to this was BL, which as expected, peaked in
children between the ages of 1-5 years. Interestingly, the
prevalence of NPC, unlike GC and HL did not continue
to increase with age. Rather, it peaked in the age groupFigure 4 Global burden of deaths from EBV-attributed malignancies i55-60 year-olds and thereafter decreased at an average of
2.75% annually (Figure 5). This trend is consistent with
previous reports [53,54].
Discussion
Epstein-Barr virus is a well-recognized carcinogen impli-
cated in the etiology of several malignancies of both
epithelial and lymphoid origin. In this study, we present
descriptive epidemiology of EBV-attributable malignan-
cies using the GBD 2010 data. In contrast to previous
studies [1,2,55], we focused exclusively on EBV-attributablen 2010.
Figure 5 Global burden of deaths from EBV-attributed malignancies by age in 2010.
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malignancies associated with this virus. In addition to
NPC, BL and HL, the current report also includes mortal-
ities from GC and PTLD, both of which are known to be
associated with EBV [42,56,57]. In this analysis, we present
the global burden of mortality from EBV-attributed malig-
nancies, stratified by age, sex and geographical region
from 1990-2010. The results of this study demonstrate
that the global burden of mortality from EBV-attributed
malignancies accounts for 1.8% of all cancer deaths in
2010. This is a 14.6% increase from 1990 and the trends
indicate that this burden will continue to increase as the
world population and life-expectancy increase [37]. Gastric
cancer and NPC accounted for 92% (132,199 cases) of
all EBV-attributed cancer deaths, with the vast majority
occurring in developing countries, in particular East
Asia. Indeed, the age-standardized rates of both of these
malignancies are also considerably higher in East Asia
compared to western countries, consistent with previ-
ous reports [58,59]. The reason for this elevated inci-
dence in certain Asian countries remains unknown, as
does the male preponderance [58]. Epidemiological
studies on NPC and GC have shown that individuals
who migrate from high-risk countries to low-risk coun-
tries have incidence rates intermediate to their country
of origin and their host country [53,59]. This impliesthat the etiology of these malignancies is complex and
most probably involves multiple factors including,
environmental, genetic and dietary. One factor in
particular, namely EBV, has been consistently shown to
be involved in the development of these malignancies
[53,56,60], but the molecular mechanism(s) involved is
not well understood. The fact that virtually all adults
worldwide are infected with EBV, and yet only a very
small fraction of individuals actually develop these
malignancies, clearly indicates that EBV alone is not
sufficient. For NPC, it has been hypothesized that
infection with EBV early in childhood, which is typical
of high-incidence regions, is important [53]. For GC, in
particular non-cardia type, Helicobacter pylori is
generally accepted to be one of the prime risk factors
[61,62]. Of the dietary and life style factors, increased
intake of salts or salt preserved food, alcohol and
smoking have been implicated, although the attributable
risk is at best only modest [53,63,64].
In contrast to NPC and GC, the role of EBV in the
development of BL, PTLD and HL is to some extent
better understood. Burkitt’s lymphoma is primarily a
childhood malignancy endemic in Sub-Saharan Africa.
Three factors have been shown to be important in the
development of this malignancy: EBV, malaria and de-
regulated activation of the c-myc oncogene [65]. In the case
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EBV infected cells express several viral latent products
[66,67], including the viral oncogene LMP-1 [68]. These
cells would normally be eliminated by the immune
system, but in immunocompromised individuals such as
transplant recipients, the infected cells proliferate un-
checked. Reversal of immunosuppression or infusion of
EBV-specific cytotoxic T-cells can prevent the development
of PTLD [69,70]. In HL, there is restricted EBV-gene
expression in the malignant cells, but crucially LMP-1 is
expressed [71] and thought to be central in the oncogenic
process [72].
Although this study presents the most comprehensive
and most up-to-date estimates of the global mortalities
from EBV-associated malignancies, it has several limita-
tions inherent in any study of this kind. First, our esti-
mates rely on the accuracy of the dataset from the GBD
2010 study. GBD 2010 is the largest and most compre-
hensive project ever conducted to measure global health
metrics and as expected, this ‘super-human’ effort had
its own limitations which have been described in detail
elsewhere [19,37,38]. Second, in calculating the mortality
of EBV-attributable fraction of NPC, GC, HL, BL and
PTLD, it was assumed that the risk of death from EBV-
positive and negative cases is the same. This may not
always be the case for all EBV-associated malignancies
[25,28,73]. Indeed, some studies have reported a better
prognosis for EBV-positive cases compared to negative
cases [25,74]. Third, to calculate the mortality of EBV-
attributable cases of BL, we first had to determine the
number of deaths from BL, as this was not directly
available from GBD 2010 data. In the GBD 2010 data,
BL was grouped in the larger category of non-Hodgkin’s
lymphoma (NHL). In calculating the mortality of BL, it
was assumed that the mortality of BL was the same as
other lymphomas in the NHL group. Once again, this
assumption is strictly speaking not true, since NHL repre-
sent a heterogeneous group of lymphomas with differing
prognoses [75]. Fifth, for calculating the proportion of
EBV-attributable malignancies at different time points i.e.
1990, 1995, 2000 and 2005, we used EBV-attributable
proportions of 97.2% for NPC, 80% for PTLD, 51.2% for
BL, 44.7% for HL and 9.2% for GC, estimated for 2010,
with the assumption that these proportions have not
changed over time. Finally, our estimate of 142,979 global
deaths from EBV-associated malignancies is likely to be an
underestimate since a few other EBV-associated malignan-
cies such as central nervous system malignancies occurring
in AIDS patients, for which there is substantial evidence
for causality [76] have not been considered in this analysis.
Conclusion
Cancer is amongst the leading causes of death. In 2010,
cancer accounted for 7.978 million deaths, and this figureappears to be rising at a rate of approximately 2% per year
[38]. Thus, understanding the risk factors or causes of
cancer is of paramount importance for any future preven-
tion strategies. The analysis presented here indicates that
1.8% of all cancer deaths in 2010 were associated with
EBV. This is a sizable number of deaths and developing
an effective vaccine would not only reduce this burden,
but could also prevent infectious mononucleosis, which is
also known to be caused by EBV [77].
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